ECZACIBASI ACQUIRES GENSENTA FOR USD 135M

The pharmaceutical company Eczacibasi Holding has reached an agreement to acquire a 99.96% share in the U.S.based pharmaceutical firm Amgen’s subsidiary Gensenta for USD 135m, according to a statement from the holding company. The acquisition will be completed following the approval of the Competition Authority. “We plan to increase our operations with innovative pharmaceuticals in different treatment fields and a wide product range at home and abroad,” said Bulent Eczacibasi, Chairman of the Board of Directors of Eczacibasi Holding. Gensenta will continue its operations and serve patients in Turkey following the acquisition. “With this acquisition, we’ll continue to grow with the power of domestic production by adding pharmaceutical and biosimilar pharmaceutical production, pharmaceutical raw material manufacturing, and export competencies in the health sector to our portfolio,” said Eczacibasi. Gensenta, which earns 47% of its revenue from exports, is among the most important lyophilized vial manufacturers and exporters in the region and Turkey. Beginning operations as a laboratory in 1923, Gensenta was acquired by the American Amgen in 2012. square meters in 40 cities across the country, including its supermarkets. The company, which operates 800 supermarkets including 100 dealers in the country, receives more than 500 dealership applications per month. YENER KARADENIZ